Reviewer's report

Title: Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model

Version: 1 Date: 5 September 2006

Reviewer: Konstantin Christov

Reviewer's report:

General
I declare that I have no competing interest's below.
Liarozole fumarate (R82246) alone and combined with tamoxifen has been used to suppress the progression of established mammary tumors in rats. Liatrozole is an aromataze inhibitor which is no more in the market. Its combination with tamoxifen is not appropriate because they work on ER + mammary tumor cells by similar mechanisms, therefore the results on tumor burden are not additive. The subcutaneous injection of tamoxifen is not the appropriate pathway for testing the efficacy of various doses. From the slides presenting the alterations in the endometrium it appears that apoptosis is strongly involved in mediating the effect of both agents.

What next?: Unable to decide on acceptance or rejection until the authors have responded to the major compulsory revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes